Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.62 |
| ▸ | CCR1 | P32246 | 6/20 | 0.57 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.57 |
| ▸ | CCR3 | P51677 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14372296 | 0.90 | DRD2 (0.54) | DRD2CCR1CHRM4CCR3DRD3 | |
| SCHEMBL14282309 | 0.87 | CHRM4 (0.61) | DRD2CCR1CHRM4DRD3ADRA1A | |
| SCHEMBL6705864 | 0.82 | CHRM4 (0.66) | DRD2CCR1CHRM4CCR3DRD3 | |
| SCHEMBL9371782 | 0.81 | DRD2 (0.60) | DRD2CCR1ADRA1A | |
| SCHEMBL5468384 | 0.80 | DRD2 (0.62) | DRD2DRD3 | |
| SCHEMBL17117407 | 0.80 | CHRM4 (0.68) | DRD2CCR1CHRM4CCR3EPHX2 | |
| SCHEMBL5462597 | 0.77 | TACR2 (0.62) | DRD2CCR1CCR3DRD3ADRA1A | |
| Hydrochloric Acid SCHEMBL8892313 | 0.77 | CHRM4 (0.54) | DRD2CCR1CHRM4CCR3DRD3 | |
| SCHEMBL7960074 | 0.75 | DRD2 (0.62) | DRD2CCR1ADRA1A | |
| SCHEMBL5468322 | 0.75 | EPHX2 (0.53) | DRD2CHRM4DRD3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | HRH3, HRH1, HRH4 | DRD2 34/4885CCR1 639/4885CHRM4 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.